Archives
-
PCI-32765 (Ibrutinib) BTK Research Workflow
2026-09-18
Build reproducible B-cell receptor experiments with PCI-32765, using dose-response, stimulation, washout, and orthogonal readouts to distinguish BTK pathway effects from nonspecific toxicity. A factorial design inspired by amyloid-model research helps extend Ibrutinib studies from simple viability assays to mechanistically informative cellular workflows.
-
Recombinant Human FGF-19: Practical Assay Guide
2026-09-17
This guide explains how to reconstitute, qualify, and apply Recombinant Human FGF-19 in receptor-binding, proliferation, and metabolic signaling workflows. It is suitable for controlled in vitro research, but the product dossier does not establish therapeutic efficacy, disease-model outcomes, or universal activity across cell types.
-
D-Luciferin for Mechanistic Cancer Imaging
2026-09-17
D-Luciferin is more than a firefly luciferase substrate: it is an analytical bridge between pathway biology, reporter assays, and longitudinal tumor imaging. This article explains how to interpret its photon signal in studies of the FGF19–ELF4–FGFR4/SRC axis while avoiding common assay-design errors.
-
Betaine-Loaded LNPs Improve mRNA Delivery After Freezing
2026-09-16
The 2025 Nature Communications study shows that freezing can do more than preserve lipid nanoparticles: freeze concentration drives betaine into LNPs, where it improves endosomal escape and mRNA delivery. The work reframes cryoprotectants as functional formulation components and provides a rationale for using reporter mRNA to evaluate post-freeze delivery performance.
-
Aβ42 as a Translational Stress Test in AD Research
2026-09-16
Amyloid β-Peptide (1-42) is more than an amyloid model: it is a controllable perturbation for linking neuronal viability, ion-channel behavior, aggregation state, and microglial phagocytosis. This translational framework shows how to use Aβ42 peptide experiments to generate more reproducible and decision-ready Alzheimer’s disease research data.
-
Berberrubine, Urate Transporters, and JAK2/STAT3
2026-09-15
The reference study shows that berberrubine reduces potassium oxonate- and hypoxanthine-induced hyperuricemia in mice through coordinated regulation of urate transporters, hepatic xanthine oxidase, inflammation, and JAK2/STAT3 signaling. Its integrated in vivo design offers a useful framework for connecting serum urate control with renal protection while highlighting the limits of extrapolating short-term animal data to clinical treatment.
-
Sorafenib (BAY-43-9006) Workflow for ATRX Models
2026-09-15
Build a more informative Sorafenib workflow by combining RAF/VEGFR pathway pharmacology with ATRX-stratified glioma assays. This guide covers solvent handling, dose design, combination testing with temozolomide, angiogenesis readouts, and troubleshooting for reproducible cancer biology research.
-
Praeruptorin A: Applied Research Workflows
2026-09-14
Praeruptorin A connects intestinal barrier repair, inflammatory signaling, ferroptosis, invasion, and cardiomyopathy research in mechanism-led workflows. This guide translates pathway evidence into practical dosing, controls, assay selection, and troubleshooting strategies.
-
From Netrin-1 Biology to Better RNA-to-cDNA Decisions
2026-09-14
The Netrin-1 adipose-remodeling study illustrates how transcript-level evidence can reshape metabolic biology—and why reverse-transcription chemistry matters when targets are scarce, structured, or mechanistically decisive. This thought-leadership guide connects the study’s PPARγ and Wnt/β-catenin findings with practical strategies for more reliable cDNA synthesis for qPCR and translational validation.
-
Hoechst 33258 in Tumor pH Assay Design
2026-09-13
Discover how Hoechst 33258, a bis-benzimide DNA stain, can serve as a nuclear endpoint in tumor pH-homeostasis studies. This guide separates DNA fluorescence from direct pH measurement and builds a rigorous workflow around orthogonal lactate, pH, imaging, and viability readouts.
-
Bestatin-Derived IRAP Inhibitors: Study Insights
2026-09-12
The reference study develops α-hydroxy-β-amino acid derivatives of bestatin as selective inhibitors of the oxytocinase-family aminopeptidase IRAP. Through stereoselective synthesis, biochemical profiling, cellular testing, and X-ray crystallography, it identifies GAMEN-loop interactions as an important determinant of potency and reports a cell-active low-nanomolar inhibitor with more than 120-fold selectivity over related enzymes.
-
Tianhuang Formula, RAGE/POMC, and Metabolic Control
2026-09-11
A 2026 pre-proof study identifies RAGE as a central nervous system target of berberine from Tianhuang Formula and connects RAGE/POMC signaling with hypothalamic neuronal apoptosis, autophagy, and glucolipid metabolism. Its integrated computational, cellular, and mouse-model design offers a mechanistic framework for metabolic neuroscience while leaving questions about causal specificity, dosing, and clinical translation unresolved.
-
Ionizable Lipids for Organ-Selective mRNA Delivery
2026-09-11
The reference study introduces Ugi four-component chemistry as a mild, modular route for rapidly building ionizable lipid libraries and identifying high-performing lipid nanoparticles for mRNA delivery. Its results show that lipid skeleton, molecular isomerism, and administration route can substantially influence whether expression is concentrated in the liver or spleen.
-
Nilotinib (AMN-107): Reliable Assay Workflows
2026-09-10
A scenario-based guide to using Nilotinib (AMN-107), SKU A8232, in kinase signaling, viability, proliferation, and cytotoxicity workflows. It connects formulation control, exposure design, and data interpretation with evidence from BCR-ABL studies and recent colorectal cancer immunobiology.
-
Praeruptorin A Research Workflow Guide
2026-09-10
Build more reliable inflammation, ferroptosis, metastasis, and cardiomyopathy studies with a pathway-guided Praeruptorin A workflow. This guide converts its solubility, dose-range, and multi-target profile into practical assay design, controls, and troubleshooting decisions.